Several other research firms have also recently commented on AMAG. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. ValuEngine cut AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 15th. Cantor Fitzgerald restated a “hold” rating and set a $14.00 price target (down previously from $17.00) on shares of AMAG Pharmaceuticals in a research note on Thursday, March 14th. Finally, SunTrust Banks began coverage on AMAG Pharmaceuticals in a research note on Tuesday, March 19th. They set a “hold” rating for the company. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $18.78.
NASDAQ AMAG traded down $0.30 on Tuesday, reaching $8.99. The stock had a trading volume of 665,500 shares, compared to its average volume of 678,319. The company has a current ratio of 2.30, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. AMAG Pharmaceuticals has a 12-month low of $8.85 and a 12-month high of $26.10. The stock has a market cap of $309.67 million, a P/E ratio of -2.32 and a beta of 0.48.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The firm had revenue of $75.80 million during the quarter, compared to analysts’ expectations of $90.13 million. During the same quarter in the prior year, the firm posted ($1.59) EPS. AMAG Pharmaceuticals’s quarterly revenue was down 35.4% compared to the same quarter last year. As a group, research analysts predict that AMAG Pharmaceuticals will post -5.72 earnings per share for the current year.
In other AMAG Pharmaceuticals news, CEO William K. Heiden bought 10,000 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, May 9th. The shares were purchased at an average cost of $10.70 per share, for a total transaction of $107,000.00. Following the completion of the transaction, the chief executive officer now owns 490,056 shares of the company’s stock, valued at approximately $5,243,599.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elizabeth Scott Bolgiano bought 5,000 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, May 9th. The shares were acquired at an average price of $10.93 per share, for a total transaction of $54,650.00. Following the completion of the transaction, the insider now directly owns 74,847 shares of the company’s stock, valued at approximately $818,077.71. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 25,000 shares of company stock worth $260,750. Corporate insiders own 4.90% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AMAG. Pearl River Capital LLC purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth about $28,000. NumerixS Investment Technologies Inc raised its holdings in shares of AMAG Pharmaceuticals by 17.8% in the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,083 shares during the period. Quantamental Technologies LLC purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth about $107,000. First Quadrant L P CA purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth about $141,000. Finally, Municipal Employees Retirement System of Michigan purchased a new position in shares of AMAG Pharmaceuticals in the 4th quarter worth about $151,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Article: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.